HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial:: an extended virology study

被引:25
|
作者
Aboulker, JP [1 ]
Babiker, AG [1 ]
Brun-Vézinet, F [1 ]
Darbyshire, JH [1 ]
Flandre, P [1 ]
Gazzard, B [1 ]
Nunn, AJ [1 ]
Goodall, R [1 ]
Aber, V [1 ]
Bragman, K [1 ]
Breckenridge, AM [1 ]
Carbon, C [1 ]
Charreau, I [1 ]
Chene, G [1 ]
Collis, P [1 ]
Cooper, D [1 ]
Dormont, J [1 ]
Fiddian, P [1 ]
Flepp, M [1 ]
Goebel, FD [1 ]
Hooker, M [1 ]
Lange, J [1 ]
Lüthy, R [1 ]
Peto, TEA [1 ]
Reiss, P [1 ]
Seligmann, M [1 ]
Stone, AB [1 ]
Thomis, J [1 ]
Vella, S [1 ]
Walckenaer, G [1 ]
Warrell, D [1 ]
Weller, IVD [1 ]
Wilber, R [1 ]
Yeni, P [1 ]
Yeo, J [1 ]
Withnall, R [1 ]
Goudsmit, J [1 ]
Huraux, JM [1 ]
van der Noorda, J [1 ]
Weiss, R [1 ]
Boucher, C [1 ]
Schuurman, R [1 ]
Descamps, D [1 ]
Jeffries, D [1 ]
Tedder, R [1 ]
Weber, J [1 ]
Krzyanowski, C [1 ]
Weverling, G [1 ]
机构
[1] UCL, Sch Med, Mortimer Market Ctr, MRC,Clin Trials Unit, London WC1E 6AU, England
关键词
antiviral therapy; progression; HIV-1; RNA; viral load;
D O I
10.1097/00002030-199901140-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess changes in HIV RNA and their relationship to disease progression. Design and setting: Delta was a randomized double-blind trial comparing zidovudine (ZDV) monotherapy with ZDV plus didanosine (ddl) or ZDV plus zalcitabine (ddC). Participants had AIDS (with CD4 cell counts above 50 x 10(6)/l), AIDS-related complex, or were asymptomatic with CD4 cell counts below 350 x 10(6)/l. The trial included both ZDV-naive and ZDV-experienced participants. Participants: A total of 1280 participants in the Delta trial whose serum samples had been stored at -70 degrees C and who had a minimum of one sample taken before the start of treatment and at least one later sample. Methods: HIV-1 RNA quantification was performed using the nucleic acid sequence-based amplification HIV-1 RNA quantitative assay with a cut-off of 800 copies/ml. Results: Reductions in HIV RNA by treatment group were consistent with the clinical results; in ZDV-naive participants the maximum median fall occurred at 4 weeks for all three groups (ZDV, 0.54 log(10) copies/ml; ZDV-ddl, 1.38 log(10) copies/ml; ZDV-ddC, 1.31 log(10), copies/ml). On average the reductions were smaller in ZDV-experienced participants but the difference between the monotherapy and combination arms was very similar in ZDV-naive and experienced participants. Baseline HIV RNA levels, adjusted for CD4 cell counts were highly predictive of time to virological response (HIV RNA < 800 copies/ml); HIV RNA nadirs achieved were predictive of survival. Viral load rebound following response was independent of treatment group and previous ZDV therapy. Conclusions: Virological changes in response to treatment are of Value in assessing prognosis and the activity of new therapies; in particular, there is a strong association between the minimum HIV RNA achieved in the first 16 weeks and subsequent clinical response. CD4 cell counts are independently predictive of response. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 50 条
  • [1] Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert
    Kim, HN
    Tabet, SR
    Corey, L
    Celum, CL
    VACCINE, 2006, 24 (04) : 532 - 539
  • [2] Antiretroviral treatment of HIV-1 infection
    Stellbrink, H. -J.
    INTERNIST, 2012, 53 (10): : 1157 - +
  • [3] Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue:: A randomized trial of double versus triple therapy
    Opravil, M
    Cone, RW
    Fischer, M
    Vernazza, PL
    Bassetti, S
    Lorenzi, P
    Bisset, LR
    Ott, P
    Huber, W
    Knuchel, MC
    Roos, M
    Lüthy, R
    Weber, R
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (01) : 17 - 25
  • [4] Antiretroviral drug treatment of CNS HIV-1 infection
    Yilmaz, Aylin
    Price, Richard W.
    Gisslen, Magnus
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (02) : 299 - 311
  • [5] Structured treatment interruptions in antiretroviral management of HIV-1
    Miller, V
    CURRENT OPINION IN INFECTIOUS DISEASES, 2001, 14 (01) : 29 - 37
  • [6] Antiretroviral Treatment Interruptions Predict Female Genital Shedding of Genotypically Resistant HIV-1 RNA
    Graham, Susan M.
    Jalalian-Lechak, Zahra
    Shafi, Juma
    Chohan, Vrasha
    Deya, Ruth W.
    Jaoko, Walter
    Mandaliya, Kishor N.
    Peshu, Norbert M.
    Overbaugh, Julie
    McClelland, R. Scott
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 60 (05) : 511 - 518
  • [7] HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial
    BrunVezinet, F
    Boucher, C
    Loveday, C
    Descamps, D
    Fauveau, V
    Izopet, J
    Jeffries, D
    Kaye, S
    Krzyanowski, C
    Nunn, A
    Schuurman, R
    Seigneurin, JM
    Tamalet, C
    Tedder, R
    Weber, J
    Weverling, GJ
    Aber, V
    Aboulker, JP
    Babiker, AG
    Bragman, K
    Breckenridge, AM
    Carbon, C
    Charreau, I
    Chene, G
    Collis, P
    Cooper, D
    Darbyshire, JH
    Dormont, J
    Fiddian, P
    Flepp, M
    Gazzard, B
    Goebel, FD
    Hooker, M
    Lange, J
    Luthy, R
    Peto, TEA
    Reiss, P
    Seligmann, M
    Stone, AB
    Thomis, J
    Vella, S
    Walckenaer, G
    Warrell, D
    Weller, IVD
    Wilber, R
    Yeni, P
    Yeo, J
    Withnall, R
    Babiker, A
    Bloch, J
    LANCET, 1997, 350 (9083): : 983 - 990
  • [8] Quinoline antimalarials as investigational drugs for HIV-1/AIDS: In vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations
    Savarino, Andrea
    Lucia, Mothanje B.
    ter Heine, Rob
    Rastrelli, Elena
    Rutella, Sergio
    Majori, Giancarlo
    Huitema, Alwin
    Boelaert, Johan R.
    Cauda, Roberto
    DRUG DEVELOPMENT RESEARCH, 2006, 67 (10) : 806 - 817
  • [9] Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
    Harrigan, PR
    Whaley, M
    Montaner, JSG
    AIDS, 1999, 13 (08) : F59 - F62
  • [10] Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy
    Lafeuillade, A
    Poggi, C
    Pellegrino, P
    Profizi, N
    INFECTION, 1996, 24 (06) : 412 - 418